Vitiligo pathophysiology: Difference between revisions
| Line 11: | Line 11: | ||
* Both cellular immunity and humoral immunity have been linked to the pathogenesis of vitiligo. | * Both cellular immunity and humoral immunity have been linked to the pathogenesis of vitiligo. | ||
** A predominance of CD8+ T bLymphocytes and Th1 CD4+ T lymphocytes has been found in vitiligo skin lesions.<ref name="pmid15654968">{{cite journal| author=Steitz J, Brück J, Lenz J, Büchs S, Tüting T| title=Peripheral CD8+ T cell tolerance against melanocytic self-antigens in the skin is regulated in two steps by CD4+ T cells and local inflammation: implications for the pathophysiology of vitiligo. | journal=J Invest Dermatol | year= 2005 | volume= 124 | issue= 1 | pages= 144-50 | pmid=15654968 | doi=10.1111/j.0022-202X.2004.23538.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15654968 }} </ref><ref name="pmid11407977">{{cite journal| author=Lang KS, Caroli CC, Muhm A, Wernet D, Moris A, Schittek B et al.| title=HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1. | journal=J Invest Dermatol | year= 2001 | volume= 116 | issue= 6 | pages= 891-7 | pmid=11407977 | doi=10.1046/j.1523-1747.2001.01363.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11407977 }} </ref> | ** A predominance of CD8+ T bLymphocytes and Th1 CD4+ T lymphocytes has been found in vitiligo skin lesions.<ref name="pmid15654968">{{cite journal| author=Steitz J, Brück J, Lenz J, Büchs S, Tüting T| title=Peripheral CD8+ T cell tolerance against melanocytic self-antigens in the skin is regulated in two steps by CD4+ T cells and local inflammation: implications for the pathophysiology of vitiligo. | journal=J Invest Dermatol | year= 2005 | volume= 124 | issue= 1 | pages= 144-50 | pmid=15654968 | doi=10.1111/j.0022-202X.2004.23538.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15654968 }} </ref><ref name="pmid11407977">{{cite journal| author=Lang KS, Caroli CC, Muhm A, Wernet D, Moris A, Schittek B et al.| title=HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1. | journal=J Invest Dermatol | year= 2001 | volume= 116 | issue= 6 | pages= 891-7 | pmid=11407977 | doi=10.1046/j.1523-1747.2001.01363.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11407977 }} </ref> | ||
** Vitiligo patients have | ** Vitiligo patients have circulating IgG and IgA autoantibodies to melanocytes proteins as tyrosinase, TYRP 1 and 2; the melanosomal matrix protein gp100 (Pmel17) and, Melan A/MART 1.<ref name="pmid17289548">{{cite journal| author=Kemp EH, Gavalas NG, Gawkrodger DJ, Weetman AP| title=Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo. | journal=Autoimmun Rev | year= 2007 | volume= 6 | issue= 3 | pages= 138-42 | pmid=17289548 | doi=10.1016/j.autrev.2006.09.010 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17289548 }} </ref><ref name="pmid20067874">{{cite journal| author=Ali R, Ahsan MS, Azad MA, Ullah MA, Bari W, Islam SN et al.| title=Immunoglobulin levels of vitiligo patients. | journal=Pak J Pharm Sci | year= 2010 | volume= 23 | issue= 1 | pages= 97-102 | pmid=20067874 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20067874 }} </ref> Passive immunization with monoclonal autoantibodies against the melanocyte membrane protein gp75 (TYRP1) in an animal model induced vitiligo-like lesions.<ref name="pmid7595233">{{cite journal| author=Hara I, Takechi Y, Houghton AN| title=Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. | journal=J Exp Med | year= 1995 | volume= 182 | issue= 5 | pages= 1609-14 | pmid=7595233 | doi= | pmc=PMC2192219 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7595233 }} </ref> | ||
==Genetics== | ==Genetics== | ||
Revision as of 20:20, 25 June 2014
|
Vitiligo Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Vitiligo pathophysiology On the Web |
|
American Roentgen Ray Society Images of Vitiligo pathophysiology |
|
Risk calculators and risk factors for Vitiligo pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Vitiligo is the most common human pigmentation disorder and is characterized by a lost of skin melanocytes. The exact mechanism is not well understood yet but apparently involves genetic predisposition, autoimmune factors, oxidative stress and sympathetic neurogenic disturbance;[1][2] probably being the autoimmune component the most important one because of all the evidence available as the association with several autoimmune conditions and the presence of autoimmune-susceptibility genes.
Pathophysiology
Immune Mechanisms
- Although there are a lot of mechanisms involved in the pathogenesis of vitiligo, the evidence of an autoimmune etiology is important.
- Both cellular immunity and humoral immunity have been linked to the pathogenesis of vitiligo.
- A predominance of CD8+ T bLymphocytes and Th1 CD4+ T lymphocytes has been found in vitiligo skin lesions.[3][4]
- Vitiligo patients have circulating IgG and IgA autoantibodies to melanocytes proteins as tyrosinase, TYRP 1 and 2; the melanosomal matrix protein gp100 (Pmel17) and, Melan A/MART 1.[5][6] Passive immunization with monoclonal autoantibodies against the melanocyte membrane protein gp75 (TYRP1) in an animal model induced vitiligo-like lesions.[7]
Genetics
Jin in the New England Journal of Medicine reported a study comparing 656 people with and without vitiligo in 114 families, which found several mutations (single-nucleotide polymorphisms) in the NALP1 gene.[8][9] The NALP1 gene, which is on chromosome 17 located at 17p13, is on a cascade that regulates inflammation and cell death, including myeloid and lymphoid cells, which are white cells that are part of the immune response. NALP1 is expressed at high levels in T cells and Langerhan's cells, white cells that are involved in skin autoimmunity.
Among the inflammatory products of NALP1 are caspase 1 and caspase 5, which activate the inflammatory cytokine interleukin-1β. Interleukin-1β is expressed at high levels in patients with vitiligo. There are compounds which inhibit caspase and interleukin-1β, and so might be useful drugs for vitiligo and associated autoimmune diseases.
Of the 656 people, 219 had vitiligo only, 70 had vitiligo with autoimmune thyroid disease, and 60 had vitiligo and other autoimmune diseases. Addison's disease (typically an autoimmune destruction of the adrenal glands) may cause vitiligo.
In one of the mutations, the amino acid leucine in the NALP1 protein was replaced by histidine (Leu155->His). The original protein and sequence is highly conserved in evolution, and found in humans, chimpanzee, rhesus monkey, and bush baby, which means that it's an important protein and an alteration is likely to be harmful.
The following is the normal DNA and protein sequence in the NALP1 gene:
| TCA | CTC | CTC | TAC | CAA |
| Ser | Leu | Leu | Tyr | Gln |
| S | L | L | Y | Q |
In some cases of vitiligo the first leucine is altered to histidine, by a Leu155→His mutation:
| TCA | CAC | CTC | TAC | CAA |
| Ser | His | Leu | Tyr | Gln |
| S | H | L | Y | Q |
(Leucine is nonpolar and hydrophobic; histidine is positively charged and hydrophilic, so it is unlikely to serve the same function.[10] [11])
The normal sequence of the DNA code for NALP1 of TCACTCCTCTACCAA is replaced in some of these vitiligo families by the sequence TCACACCTCTACCAA,[12] which respectively code for the amino acid sequence of the normal NALP1 protein SLLYQ being replaced by SHLYQ.[13]
Associated Conditions
Vitiligo is associated with autoimmune and inflammatory diseases, commonly thyroid overexpression and underexpression.
Gross Pathology
Microscopic Pathology
References
- ↑ Gauthier Y, Cario Andre M, Taïeb A (2003). "A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy?". Pigment Cell Res. 16 (4): 322–32. PMID 12859615.
- ↑ Dell'anna ML, Picardo M (2006). "A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo". Pigment Cell Res. 19 (5): 406–11. doi:10.1111/j.1600-0749.2006.00333.x. PMID 16965269.
- ↑ Steitz J, Brück J, Lenz J, Büchs S, Tüting T (2005). "Peripheral CD8+ T cell tolerance against melanocytic self-antigens in the skin is regulated in two steps by CD4+ T cells and local inflammation: implications for the pathophysiology of vitiligo". J Invest Dermatol. 124 (1): 144–50. doi:10.1111/j.0022-202X.2004.23538.x. PMID 15654968.
- ↑ Lang KS, Caroli CC, Muhm A, Wernet D, Moris A, Schittek B; et al. (2001). "HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1". J Invest Dermatol. 116 (6): 891–7. doi:10.1046/j.1523-1747.2001.01363.x. PMID 11407977.
- ↑ Kemp EH, Gavalas NG, Gawkrodger DJ, Weetman AP (2007). "Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo". Autoimmun Rev. 6 (3): 138–42. doi:10.1016/j.autrev.2006.09.010. PMID 17289548.
- ↑ Ali R, Ahsan MS, Azad MA, Ullah MA, Bari W, Islam SN; et al. (2010). "Immunoglobulin levels of vitiligo patients". Pak J Pharm Sci. 23 (1): 97–102. PMID 20067874.
- ↑ Hara I, Takechi Y, Houghton AN (1995). "Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein". J Exp Med. 182 (5): 1609–14. PMC 2192219. PMID 7595233.
- ↑ Gregersen PK (2007). "Modern genetics, ancient defenses, and potential therapies". N. Engl. J. Med. 356 (12): 1263–6. doi:10.1056/NEJMe078017. PMID 17377166.
- ↑ Jin Y, Mailloux CM, Gowan K, Riccardi SL, LaBerge G, Bennett DC, Fain PR, Spritz RA (2007). "NALP1 in vitiligo-associated multiple autoimmune disease". N. Engl. J. Med. 356 (12): 1216–25. doi:10.1056/NEJMoa061592. PMID 17377159.
- ↑ List of Amino Acids and Their Abbreviations
- ↑ The Genetic Code (DNA)
- ↑ Ensembl Transcript Report Ensembl Transcript ID: NST00000262467
- ↑ Ensembl Protein Report Ensembl Peptide: ID ENSP00000262467